Ribozyme-mediated inhibition of PKCα sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis

Prostate

Volumn 54, Issue 2, 2003, Pages 133-143

  Orlandi, Linda ^a   Binda, Mara ^a   Folini, Marco ^a   Bearzatto, Alessandra ^a   Villa, Raffaella ^a   Daidone, Maria Grazia ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Cisplatin; Oxaliplatin; Protein kinase C ; Ribozyme

Indexed keywords

ANDROGEN; CISPLATIN; MESSENGER RNA; OXALIPLATIN; PROTEIN KINASE C ALPHA; RIBOZYME;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CODON; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DRUG RESISTANCE; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE DELETION; GENE INSERTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RNA TRANSCRIPTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CISPLATIN; CLONING, MOLECULAR; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOENZYMES; MALE; MOLECULAR SEQUENCE DATA; ORGANOPLATINUM COMPOUNDS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RNA, CATALYTIC; TUMOR CELLS, CULTURED;

EID: 0037304334     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10181     Document Type: Article

References (31)

1. Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000;42:247-252.
2. Landis SH, Murray T, Bolden S, Wigo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
3. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15-24.
4. Beer T, Raghavan D. Chemotherapy for hormone refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 2000;45:184-193.
5. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and the therapy for prostate cancer. Prostate 1996;28:251-265.
6. Westin P, Bergh A. Apoptosis and other mechanisms in androgen ablation treatment and androgen-independent progression of prostate cancer: A review. Cancer Detect Prev 1998; 22:476-484.
7. Coffey RNT, Watson WG, Fitzpatrick JM. Signaling for the caspases: Their role in prostate cell apoptosis. J Urol 2001;165:4-14.
8. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996;8:168-173.
9. Deacon EM, Pongracz J, Griffith G, Lord JM. Isoenzymes of protein kinase C: Differential involvement in apoptosis and pathogenesis. J Clin Pathol: Mol Pathol 1997;50:124-131.
10. Dooley NP, Baltuch GH, Groome N, Villemure JG, Yong VW. Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide. Neuroreport 1998;9:1727-1733.
11. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D, Dean NM. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: In vitro and in vivo activity, and clinical development as anti-cancer therapeutics. Anticancer Drug Des 1997;12:315-326.
12. Geiger T, Muller M, Dean NM, Fabbro D. Antitumor activity of a PKC alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998;13:35-45.
13. Powell CT, Brittis NJ, Stec D, Hug H, Heston WDW, Fair WR. Persistent membrane translocation of protein kinase Cα during 12-O-tetradecanoylphorbol-13-acetate induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 1996; 7:419-428.
14. O'Brian CA. Protein kinase C alpha: A novel target for the therapy of androgen independent prostate cancer? Oncol Reports 1998;5:305-309.
15. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978;21:274-281.
16. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishement and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
17. Sioud M, Drlica K. Prevention of HIV-1 integrase expression in E. coli by a ribozyme. Proc Natl Acad Sci USA 1991;88:7303-7307.
18. Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase Cα triggers apoptosis in glioma cells. Br J Cancer 1999;80:1558-1564.
19. waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer 1999;81:252-260.
20. Basu A, Weixel KM. Comparison of proteine kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int J Cancer 1995;62:457-460.
21. Hoffmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001;142:1-96.
22. Sioud M, Sorensen DR. A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth. Nat Biotechnol 1998;16:556-561.
23. Howell SB. Resistance to apoptosis in prostate cancer cells. Mol Urol 2001;4:225-229.
24. Isonishi S, Ohkawa K, Tanaka T, Howell SB. Depletion of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 2000;82:34-38.
25. Spitaler M, Wiesenhofer B, Biedermann V, Seppi T, Zimmermann J, Grunicke H, Hofmann J. The involvement of protein kinase C α, ε, and ζ in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res 1999;19:3969-3976.
26. Colella G, Pennati M, Bearzatto A, Leone R, Colangelo D, Manzotti C, Daidone MG, Zaffaroni N. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: Cytotoxicity and induction and gene specific repair of DNA lesions. Br J Cancer 2001;84:1387-1390.
27. Orlandi L, Colella G, Bearzatto A,5 Abolafio G, Manzotti C, Daidone MG, Zaffaroni N. Effects of a novel trinuclear platinum complex in cisplatin sensitive and resistant human ovarian cancer cell lines: Interference with cell cycle progression and induction of apoptosis. Eur J Cancer 2001;37:649-659.
28. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 2001;59:657-663.
29. Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999;59:382-390.
30. Bowen C, Voeller HJ, Kikly K, Gelmann EP. Synthesis of procaspase-3 and -7 during apoptosis in prostate cancer cells. Cell Death Diff 1999;6:394-401.
31. Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense therapeutics: Lessons from early clinical trials. Curr Opin Oncol 2001;13:499-505.